Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients With, Lymphomas, Chronic Lymphocytic Leukemia, and Select Solid Tumors and Varying Degrees of Liver Dysfunction

NCT01638533 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01638533
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01638533 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients With, Lymphomas, Chronic Lymphocytic Leukemia, and Select Solid Tumors and Varying Degrees of Liver Dysfunction
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Completed
Start date
August 3, 2012
Completion date
September 1, 2020
Enrollment
37 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

glioma, hematopoietic and lymphoid cell neoplasm, lymphoma, metastatic malignant solid neoplasm, neuroendocrine neoplasm, recurrent adult soft tissue sarcoma, recurrent bladder carcinoma, recurrent breast carcinoma, recurrent chronic lymphocytic leukemia, recurrent colorectal carcinoma, recurrent head and neck carcinoma, recurrent lung carcinoma, recurrent malignant solid neoplasm, recurrent melanoma, recurrent pancreatic carcinoma, recurrent primary cutaneous t-cell non-hodgkin lymphoma, recurrent prostate carcinoma, recurrent renal cell carcinoma, recurrent thyroid gland carcinoma, refractory chronic lymphocytic leukemia, refractory mature t-cell and nk-cell non-hodgkin lymphoma, refractory primary cutaneous t-cell non-hodgkin lymphoma, stage iii breast cancer ajcc v7, stage iii colorectal cancer ajcc v7, stage iii cutaneous melanoma ajcc v7, stage iii lung cancer ajcc v7, stage iii pancreatic cancer ajcc v6 and v7, stage iii prostate cancer ajcc v7, stage iii renal cell cancer ajcc v7, stage iii soft tissue sarcoma ajcc v7, stage iiia breast cancer ajcc v7, stage iiia colorectal cancer ajcc v7, stage iiia cutaneous melanoma ajcc v7, stage iiib breast cancer ajcc v7, stage iiib colorectal cancer ajcc v7, stage iiib cutaneous melanoma ajcc v7, stage iiic breast cancer ajcc v7, stage iiic colorectal cancer ajcc v7, stage iiic cutaneous melanoma ajcc v7, stage iv breast cancer ajcc v6 and v7, stage iv colorectal cancer ajcc v7, stage iv cutaneous melanoma ajcc v6 and v7, stage iv lung cancer ajcc v7, stage iv pancreatic cancer ajcc v6 and v7, stage iv prostate cancer ajcc v7, stage iv renal cell cancer ajcc v7, stage iv soft tissue sarcoma ajcc v7, stage iva colorectal cancer ajcc v7, stage ivb colorectal cancer ajcc v7, unresectable solid neoplasm